Stage 4 pancreatic cancer treatment options have evolved significantly beyond chemotherapy alone, with personalized approaches now guiding decisions based on tumor biology, genetic markers, performance status, and patient goals rather than one-size-fits-all protocols. TL;DR Only 15 to 20% of pancreatic cancers are diagnosed at a potentially resectable stage, making stage 4 treatment focused on extending life, managing symptoms, and maintaining quality of life [1] FOLFIRINOX a